Peginterferon beta - Bolder BioTechnology

Drug Profile

Peginterferon beta - Bolder BioTechnology

Alternative Names: BBT-032; PegIFN-beta - Bolder BioTechnology; PegIFN-β - Bolder Biotechnology

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bolder BioTechnology
  • Class Interferons
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis
  • Discontinued Cancer

Most Recent Events

  • 04 Dec 2017 Peginterferon beta is still in preclinical development for Multiple sclerosis in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Discontinued - Preclinical for Cancer in USA (Parenteral) before November 2017 (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Bolder Biotechnology plans a clinical trial for Multiple sclerosis in 2018 (Bolder Biotechnology pipeline, December 22015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top